Acorys System Gains FDA Clearance for Real-Time 4D Cardiac Mapping

Key Takeaways

• FDA clears Corify Care’s Acorys 4D cardiac mapping platform
• System provides real‑time, four‑chamber electrical view without CT/MRI
• Evaluated in over 2,500 European EP patients, guiding ablation targets
• Enables global mapping from a single heartbeat, reducing procedure time
• US rollout begins with phased launch at selected electrophysiology centers

Pulse Analysis

The Acorys system represents a shift toward truly imageless cardiac mapping, merging three‑dimensional anatomy with temporal electrical data to produce a four‑dimensional view of the heart. By eliminating pre‑procedural CT or MRI, the platform sidesteps radiation exposure, reduces scheduling bottlenecks, and cuts equipment costs. Clinicians can visualize how electrical signals propagate across all chambers in real time, enabling faster identification of arrhythmia mechanisms and more precise ablation targeting during a single heartbeat.

In the competitive landscape, Acorys joins Abbott’s EnSite X and Medtronic’s CardioInsight as leaders in advanced EP visualization, but it differentiates itself through its non‑invasive workflow and rapid mapping speed. Recent FDA clearances for Vektor’s vMap and Boston Scientific’s planned Cortex acquisition underscore a market hungry for tools that simplify complex arrhythmia cases. The trend toward software‑centric, data‑driven solutions is attracting both venture capital and strategic M&A activity, suggesting that companies able to deliver accurate, real‑time insights without bulky hardware will capture significant market share.

Clinically, the ability to map ventricular tachycardia substrates during sinus rhythm could reduce the need to induce unstable arrhythmias, lowering procedural risk. The system’s performance in over 2,500 patients provides a robust data foundation for broader adoption, and its upcoming U.S. rollout targets high‑volume EP centers that can validate its efficiency gains. As the Heart Rhythm Society’s 2026 meeting approaches, further trial results are expected, potentially expanding indications beyond ablation to cardiac resynchronization therapy planning and broader electrophysiology diagnostics.